Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.

2型糖尿病 利拉鲁肽 二甲双胍 艾塞那肽 体质指数 胰高血糖素样肽1受体 胰岛素 胰岛素抵抗 胰高血糖素样肽-1 血糖性 安慰剂
作者
Fang Zhang,Lizhi Tang,Yuwei Zhang,Qingguo Lü,Nanwei Tong
出处
期刊:Scientific Reports [Springer Nature]
卷期号:7 (1): 15997-15997 被引量:11
标识
DOI:10.1038/s41598-017-16018-9
摘要

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity. We aimed to determine whether GLP-1RAs exhibit different glucose-lowering efficacies between Asian type 2 diabetes (T2D) patients with and without overweight/obesity. Randomized controlled trials were searched in EMBASE, MEDLINE, CENTRAL, and ClinicalTrials.gov. Studies published in English with treatment duration ≥12 weeks and information on HbA1c changes were included. The studies were divided into normal body mass index (BMI) and overweight/obese groups according to baseline BMI. Among 3190 searched studies, 20 trials were included in the meta-analysis. The standardized mean differences in HbA1c change, fasting glucose change, and postprandial glucose change were equivalent between normal BMI and overweight/obese studies (p > 0.05). The relative risk of HbA1c < 6.5% target achievement in normal BMI trials (7.93; 95% confidence interval: 3.27, 19.20) was superior to that in overweight/obesity trials (2.23; 1.67, 2.97), with a significant difference (p = 0.020). Body weight loss (p = 0.572) and hypoglycemic risk(p = 0.920) were similar in the two groups. The glucose-lowering effects of GLP-1RAs were equivalent among Asian T2D patients. With their advantages for weight-loss or weight-maintenance, GLP-1RAs are optimal medicines for Asian T2D patients with and without overweight/obesity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ddsgsd完成签到,获得积分10
刚刚
1秒前
嗯哼应助leizi采纳,获得20
1秒前
1秒前
1秒前
Jiang完成签到,获得积分10
1秒前
阿莫西林发布了新的文献求助10
1秒前
1秒前
2秒前
RUC_Zhao发布了新的文献求助10
2秒前
020907完成签到 ,获得积分10
5秒前
无限的紫蓝完成签到 ,获得积分10
5秒前
YYJ发布了新的文献求助10
6秒前
落寞大侠发布了新的文献求助10
7秒前
7秒前
小炮仗完成签到 ,获得积分10
7秒前
李健应助小不采纳,获得10
10秒前
10秒前
11秒前
阿莫西林完成签到,获得积分10
12秒前
14秒前
义气的身影完成签到,获得积分10
14秒前
15秒前
无花果应助吱吱采纳,获得10
16秒前
Lucas应助YYJ采纳,获得10
17秒前
大宝完成签到,获得积分10
17秒前
18秒前
18秒前
小邢一定行完成签到,获得积分10
19秒前
NMR完成签到,获得积分10
19秒前
小不完成签到 ,获得积分10
21秒前
漆玖完成签到,获得积分10
21秒前
wang完成签到,获得积分10
22秒前
我是老大应助朴素的清采纳,获得30
23秒前
zqy发布了新的文献求助10
23秒前
嵇凡桃完成签到,获得积分10
23秒前
lg给lg的求助进行了留言
24秒前
24秒前
刘总完成签到,获得积分10
25秒前
27秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3079267
求助须知:如何正确求助?哪些是违规求助? 2731896
关于积分的说明 7521337
捐赠科研通 2380638
什么是DOI,文献DOI怎么找? 1262413
科研通“疑难数据库(出版商)”最低求助积分说明 611928
版权声明 597414